Rimonabant for overweight and "metabolic syndrome": the attempt to supersize disease and risk by pharmaceutical marketing.

نویسندگان

  • Rita Banzi
  • Lorenzo Moja
  • Ivan Moschetti
  • Alessandro Liberati
  • Gian Franco Gensini
  • Roberto Gusinu
  • Andrea A Conti
چکیده

A Cochrane systematic review explored the potential role of rimonabant for overweight and obesity [1]. On the basis of surrogate outcomes reported in the included RCTs, rimonabant has been a candidate (by its producer) to act as a pleiotropic agent for the entire cardiovascular risk spectrum. Is this compelling evidence to consider rimonabant the new panacea for the ‘‘metabolic syndrome’’ or are we facing another attempt of disease mongering by a new market frontier? Rimonabant has been shown to reduce food intake, appetite and body weight in overweight or obese people. Four randomized controlled trials (RIO-Europe [2], RIONorth America [3], RIO-diabetes [4], RIO-lipids [5]) evaluated rimonabant 20 mg versus rimonabant 5 mg versus placebo. All interventions were given over 1 year and included the addition of a hypocaloric diet. All trials were designed, conducted and reported with the contribution of Sanofi-Aventis drug company. The Cochrane review (‘‘Rimonabant for overweight and obesity’’) [1] includes evidence from these four trials.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

تعیین شیوع سندرم متابولیک بین کودکان9-3 ساله در مطالعه قند و لیپید تهران

Background: The metabolic syndrome is a constellation of risk factors that increase the incidence of cardiovascular disease and type 2 diabetes mellitus in adults. Some studies in recent years have found evidence of initiation of this disease in childhood and of the association of childhood obesity with adult cardiovascular disease and diabetes. The present study was carried out to determine th...

متن کامل

Upper Normal Limit of Thyroid-Stimulating Hormone and Metabolic Syndrome in Iranian Patients with Obesity

Background:The current study aimed at evaluating the association between thyroid-stimulating hormone (TSH) level in upper normal limits with metabolic syndrome, modifiable risk factor for cardiovascular disease, and its components according to Adult Treatment Panel III of National Cholesterol Education Program. Methods</...

متن کامل

A Review of Neck Circumference As a Potent Anthropometric Predictor of Cardiovascular Disease and Metabolic Syndrome

Introduction: Obesity is considered to be a major risk factor for metabolic syndrome (MetS). The present study aimed to investigate the associations of neck circumference (NC) with cardiovascular diseases and MetS in adults. Methods: This review was conducted via searching in databases such as Medline, PubMed, Scopus, and Google Scholar using various keywords, ...

متن کامل

Rimonabant: the evidence for its use in the treatment of obesity and the metabolic syndrome

INTRODUCTION Obesity and overweight affect over 1 billion people worldwide and are leading causes of morbidity and mortality. Clinical features of obesity converge with those of the metabolic syndrome and type 2 diabetes, greatly increasing the risk of long-term adverse outcomes. AIMS To review the evidence on rimonabant, a novel CB1 receptor antagonist, for the treatment of obese and overwei...

متن کامل

The endocanabinnoid system and diabetes - critical analyses of studies conducted with rimonabant

Rimonabant is the first CB1 receptor inhibitor available in the Brazilian market. This new drug has been approved for the treatment of obese or overweight patients associated with cardiovascular risk factors. In this article it is compared the effects of rimonabant treatment in obese patients with cardiovascular risk factors to usual obesity pharmacological treatment.

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Internal and emergency medicine

دوره 3 1  شماره 

صفحات  -

تاریخ انتشار 2008